Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
|
By LabMedica International staff writers Posted on 22 Jan 2024 |
|
Fujirebio Holdings (Tokyo, Japan) and Agappe Diagnostics (Kochi, India) have entered into a Contract Development and Manufacturing Organization (CDMO) partnership for manufacturing cartridge-based CLIA system reagents for the Mispa i60 and Mispa i121 immunology analyzers. These analyzers and reagents will be sold under Agappe’s brand, making it the first Indian local company with a complete chemiluminescence solution made from reagents produced domestically.
The companies have outlined plans to launch these products in June 2024. Significant milestones have already been achieved, including the finalization of a supply and license agreement in March 2023. Agappe is currently in the advanced stages of technical transfer from Fujirebio, which will enable the Indian company to manufacture chemiluminescence reagents using Fujirebio’s technology and materials. The collaboration is set to make a substantial impact, with phased launches planned for a complete range of over 30 parameters, spanning various medical segments such as oncology, thyroid, cardiac, fertility, and infectious diseases. Additionally, Fujirebio’s groundbreaking biomarkers for Alzheimer’s and other neurodegenerative diseases are also included in this project.
Under this agreement, Fujirebio will be responsible for supplying the Mispa i60 and i121 analyzers and the raw materials for the reagents. Agappe, on the other hand, will focus on developing and manufacturing reagents specifically tailored for these instruments, ensuring compliance with all regulatory requirements. This partnership is based on a shared vision of leveraging each company’s unique strengths to not only foster growth in India's immunoassay market but also to significantly contribute to the advancement and enhancement of immunoassay solutions within the Indian healthcare sector.
“This partnership with Agappe, the renowned market leader with years of success in clinical chemistry, hematology, immunochemistry, and point of care in India, will accelerate our CDMO strategy in one of the most important and fastest growing countries in the world,” said Goki Ishikawa, President and CEO, Fujirebio Holdings, Inc. “We share a vision that, combining mutually complementary strengths of both companies, Agappe together with Fujirebio can deliver high-quality chemiluminescence solutions with cost competitiveness and contribute to the healthcare advancement in India.”
“Leveraging the combined strengths of Agappe and Fujirebio, we are committed to introducing high quality, affordable, and unique chemiluminescence solutions for the country,” added Thomas John, Managing Director, Agappe Diagnostics, Ltd. “This partnership symbolizes our dedication to innovation and our pledge to make advanced diagnostic products more accessible to every Indian. We are poised to set new benchmarks in the industry, emphasizing our joint endeavor to enhance healthcare standards across our nation."
Related Links:
Fujirebio Holdings
Agappe Diagnostics
Latest Industry News
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
- Bio-Rad and Biodesix Partner to Develop Droplet Digital PCR High Complexity Assays
- Hologic to be Acquired by Blackstone and TPG
- Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio
- Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders
- Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes
- GSI Group Acquires Blood Processing Equipment Manufacturer GenesisBPS
- ELITech and Hitachi High-Tech to Develop Automated PCR Testing System for Infectious Diseases
- Lumiquick Acquires Aoxre to Expand Global IVD and Research Capabilities
- Lunit and Agilent Partner to Develop AI-Powered Cancer Diagnostics
Channels
Clinical Chemistry
view channel
Compact Raman Imaging System Detects Subtle Tumor Signals
Accurate cancer diagnosis often depends on labor-intensive tissue staining and expert pathological review, which can delay results and limit access to rapid screening. These conventional methods also make... Read more
Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
People with diabetes often need to measure their blood glucose multiple times a day, most commonly through finger-prick blood tests or implanted sensors. These methods can be painful, inconvenient, and... Read more
Molecular Diagnostics
view channel
Urine Test Could Reveal Real Age and Life Span
Chronological age does not always reflect how quickly the body is aging, as biological age is shaped by genetics, stress, sleep, nutrition, and lifestyle factors such as smoking. A higher biological age... Read more
Genomic Test Identifies African Americans at Risk for Early Prostate Cancer Recurrence
Prostate cancer is one of the most commonly diagnosed cancers in men and a leading cause of cancer-related death, particularly in the United States. African American men face a disproportionately higher... Read more
Hematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read more
Microbiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read more
Pathology
view channel
Genetics and AI Improve Diagnosis of Aortic Stenosis
Aortic stenosis is a progressive narrowing of the aortic valve that restricts blood flow from the heart and can be fatal if left untreated. There are currently no medical therapies that can prevent or... Read more
AI Tool Simultaneously Identifies Genetic Mutations and Disease Type
Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups
Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Tumor Signals in Saliva and Blood Enable Non-Invasive Monitoring of Head and Neck Cancer
Head and neck cancers are among the most aggressive malignancies worldwide, with nearly 900,000 new cases diagnosed each year. Monitoring these cancers for recurrence or relapse typically relies on tissue... Read moreTechnology
view channel
AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read more
